3,6-Disubstituted xanthylium salts

Research output: Patent

Abstract

This invention pertains generally to processes, uses, methods and materials utilising
particular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer’s disease.
Original languageEnglish
IPCWO2010/067078
Publication statusPublished - 17 Jun 2010

Fingerprint

Patents and inventions
Salts
Pharmaceutical Preparations
xanthylium

Cite this

@misc{bbd3cbc683cd4a6faa5bade200e33de1,
title = "3,6-Disubstituted xanthylium salts",
abstract = "This invention pertains generally to processes, uses, methods and materials utilisingparticular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer’s disease.",
author = "Scott Clunas and Storey, {John Mervyn David} and David Horsley and Rickard, {Janet Elizabeth} and Harrington, {Charles Robert} and Wischik, {Claude Michel}",
year = "2010",
month = "6",
day = "17",
language = "English",
type = "Patent",
note = "WO2010/067078",

}

TY - PAT

T1 - 3,6-Disubstituted xanthylium salts

AU - Clunas, Scott

AU - Storey, John Mervyn David

AU - Horsley, David

AU - Rickard, Janet Elizabeth

AU - Harrington, Charles Robert

AU - Wischik, Claude Michel

PY - 2010/6/17

Y1 - 2010/6/17

N2 - This invention pertains generally to processes, uses, methods and materials utilisingparticular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer’s disease.

AB - This invention pertains generally to processes, uses, methods and materials utilisingparticular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer’s disease.

M3 - Patent

ER -